Add to Favorites
Alternative Name
FLT3, FLT3 TKD, FLT3 ITD, FLT3 Liquid Biopsy Testing
Methodology
Molecular
Test Description

Detection of internal tandem duplication and exon 20 tyrosine kinase domain (TKD) mutations using bidirectional sequencing. Positive results identify specific TKD mutations or report ITD results quantitatively as percent abnormal ITD peak. Testing is performed on cell-free plasma DNA/RNA to increase sensitivity.

Clinical Significance

Testing for FLT3 and other gene mutations in AML patients can improve risk stratification. The presence of an FLT3 mutation in a patient with AML implies aggressive disease. In addition, this test can be used for screening and determining if a bone marrow biopsy is an absolute necessity, as well as monitoring disease status and response to therapy. For FLT3-ITD, results are quantitative and help in monitoring. It can also be used for performing molecular studies when a bone marrow sample is inadequate (dry tap, insufficient quantity, or not viable), or not available.

Specimen Requirements
  • Peripheral blood: 2 x 6 mL EDTA tubes (total 12 mL) or 10 mL in EDTA tube.
Storage and Transportation

Use cold pack for transport, making sure cold pack is not in direct contact with specimen. Ship same day as drawn whenever possible; specimens <72 hours old preferred.

CPT Code(s)*
81245, 81246
Medicare MolDX CPT Code(s)*
81479
Turnaround Time

7 days

Level of Service
Global

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed.